Jubilant Pharma Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Jubilant Pharma's estimated annual revenue is currently $48.4M per year.(i)
  • Jubilant Pharma's estimated revenue per employee is $201,000

Employee Data

  • Jubilant Pharma has 241 Employees.(i)
  • Jubilant Pharma grew their employee count by -2% last year.

Jubilant Pharma's People

NameTitleEmail/Phone
1
Head Digital and IT North AmericaReveal Email/Phone
2
Head ProjectsReveal Email/Phone
3
Quality Assurance OfficerReveal Email/Phone
4
VP & Head - Business Development In-licensing External Mfg & Strategic AlliancesReveal Email/Phone
5
Sr. Director, Corporate Quality ComplianceReveal Email/Phone
6
QA Associate Director, CSV & Data GovernanceReveal Email/Phone
7
Director and Head – Financial Planning and AnalysisReveal Email/Phone
8
Corporate Quality Systems ManagerReveal Email/Phone
9
Sr. Manager, SAP ApplicationReveal Email/Phone
10
Finance ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M1928%N/AN/A
#2
$81.8M3463%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M178-3%N/AN/A
#6
$13.1M50-7%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M68-4%N/AN/A
#9
$67.9M40230%N/AN/A
#10
$14.9M51-16%N/AN/A
Add Company

What Is Jubilant Pharma?

Jubilant Pharma is a global integrated pharmaceutical company offering a wide range of products and services to our customers across geographies. We organize our business into two segments, namely, Specialty Pharmaceuticals, comprising Radiopharmaceuticals (including Radiopharmacies), Contract Manufacturing of Sterile Injectables and Non-sterile Products and Allergy Therapy Products, and Generics & APIs, comprising Solid Dosage Formulations and Active Pharmaceutical Ingredients.

keywords:N/A

N/A

Total Funding

241

Number of Employees

$48.4M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$87.9M50210%N/A
#2
$190.2M80624%N/A
#3
$46.4M80775%N/A